Lucentis News
Most Popular Lucentis Story
Novartis nabs Chinese OK for Lucentis, launches Galvus
Novartis ($NVS) has gotten a double boost in China. First, the government approved its eye drug Lucentis, and second, the company launched its diabetes medication Galvus. Lucentis, an injectable Read more...
Latest Headlines
- January 18, 2012
- January 3, 2012
- December 5, 2011
- November 30, 2011
- November 28, 2011
- November 21, 2011
- October 14, 2011
- October 6, 2011
- September 7, 2011
- July 6, 2011
- April 29, 2011
- April 28, 2011
- April 21, 2011
- April 5, 2011
- March 4, 2011
- February 2, 2011
- January 4, 2011
- November 4, 2010
- October 4, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
